Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
What was good news for Pfizer, Inc. (NYSE: PFE) turned out to be negative for several others engaged in COVID-19 vaccine and treatment research. Pfizer announced Friday its oral COVID-19 pill Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89%.
Merck & Co., Inc. (MRK: NYSE), which also has a competing medication in the pipeline, shed close to 10% on Friday.
Stocks also reacted to the earnings, which came in thick and fast during the week. Five stocks belonging to the biotech and diagnostics spaces, debuted on Wall Street during the week.
Here are the key upcoming catalysts that biotech investors are on in the unfolding week:
Health Care Conferences:
American College of Rheumatology, or ACR, Convergence 2021: Nov. 3-9 (virtual)
BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology: Nov. 8 (virtual event)
Credit Suisse 30th Annual Virtual Healthcare Conference: Nov. 8-11 (virtual conference)
14th Clinical Trial On Alzheimer's Disease, or CTAD, 2021: Nov. 9-12 (in Boston)
6th Respiratory Syncytial Virus Network, or RESVINET, Conference: Nov. 10-12 (virtual meeting)
Society For Immunotherapy of Cancer: Nov. 10-14 (hybrid event, to be held in Washington, D.C. and to be available virtually)
Connective Tissue Oncology Society, or CTOS, 2021 Annual Meeting: Nov. 10-13 (virtual meeting)
American Academy of Ophthalmology, or AAO, 2021 Meeting: Nov. 12-13 (in New Orleans)
American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2021: Nov. 12-15 (virtual meeting)
Clinical Readouts/Presentations
Liver Meeting Presentations
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA): Phase 1b data for EDP-514 in viremic, chronic hepatitis B infected patients
Vir Biotechnology, Inc. (NASDAQ: VIR): Preliminary results from a Phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody, for hepatitis B infection (Friday, at 8 a.m.)
Vaccitech plc (NASDAQ: VACC): Interim results of HBV001, a Phase 1 study evaluating therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection; Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with Bristol-Myers Squibb Company's (NYSE: BMY) low-dose Opdivo in virally-suppressed patients with CHB under nucleos(t)ide analogues
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA): results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346, which Dicerna is developing in collaboration with Roche Holding AG (OTC: RHHBY) for the treatment of chronic hepatitis B virus infection; interim Phase 1 data from Belcesiran in Alpha 1-antitrypsin deficiency-associated liver disease
Lipocine Inc. (NASDAQ: LPCN): safety And tolerability Of LPCN 1144 treatment In biopsy confirmed NASH subjects from the Phase 2 LiFT study
Arbutus Biopharma Corporation (NASDAQ: ABUS): data on the effects of its ...
Benzinga
